Please wait a minute...
Shopping Cart Email List Chinese
Advanced Search Fig/Tab
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Featured Articles  |  Most Downloaded  |  Most Reading
Online Submission Subscribe to Our RSS Content Feed
Front Med Chin    2009, Vol. 3 Issue (1) : 100-107    https://doi.org/10.1007/s11684-009-0013-x
RESEARCH ARTCILE
Expression of integrin in hepatic fibrosis and intervention of resveratrol
Jianye WU, Chuanyong GUO(email.png), Jun LIU, Xuanfu XUAN
Department of Gastroenterology, Tenth People’s Hospital of Tongji University, Shanghai 200072, China
 Download: PDF(302 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

The aim of this study was to explore the expression of integrin-β1 in different stages of hepatic fibrosis and intervention of resveratrol as well as the way by which integrin-β1 promoted hepatic fibrosis. Hepatic fibrosis models of male Sprague Dawley (SD) rats were created and intragastric administration of resveratrol was given in low (40 mg/kg), middle (120 mg/kg) and high (200 mg/kg) dose groups. The expression of integrin-β1, tumor growth factor-β (TGF-β) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in different stages of hepatic fibrosis was detected by using RT-PCR. The expression of hexadecenoic acid (HA) and precollagen III (pc III) was assayed by radioimmunoassay. The expression of integrin-β1, TGF-β and TIMP-1 was determined in each group. Liver function and pathological sections of each group in different stages of hepatic fibrosis was tested to judge the therapeutic efficacy of resveratrol at different doses. The expression of integrin-β1 in normal control group was low and steady and was not increased as the development of hepatic fibrosis, but it is increased in other groups. The expression levels of integrin-β1 in the model control group (0.878±0.03, P<0.01) and low dose group (0.855±0.04, P<0.01) were higher than other groups, but there was no difference between model control group and low dose group (P>0.05). The expression levels of integrin-β1 and TGF-β in middle dose group and high dose group were higher than other groups (P<0.01). The expression levels of integrin-β1 and TGF-β in model control group and low dose group were lower than the normal control group (P<0.01). The expression levels of TIMP-1 in the model control and low dose groups were higher than the other groups (P<0.01). The expression levels of TIMP-1 in the middle dose group and the high dose group were lower than the normal control group (P<0.01). The expression of integrin-β1 existed in all stages of hepatic fibrosis of SD rats, and it was increased as the development of hepatic fibrosis. The expression of TGF-β and TIMP-1 was consistent with that of integrin-β1 in different stages of hepatic fibrosis. Resveratrol could improve the degree of hepatic fibrosis of SD rats and decrease the expression of integrin-β1 markedly at a dose of 120 mg/kg.
Keywords liver fibrosis      integrin-β1      resveratrol      tumor growth factor-β      tissue inhibitor of metalloproteinase-1     
Corresponding Author(s): GUO Chuanyong,Email:guochuanyong@hotmail.com   
Issue Date: 05 March 2009
 Cite this article:   
Jianye WU,Chuanyong GUO,Jun LIU, et al. Expression of integrin in hepatic fibrosis and intervention of resveratrol[J]. Front Med Chin, 2009, 3(1): 100-107.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0013-x
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I1/100
Fig.1  Pathological section of each group at week 12 by Hematoxylin-Eosin staining (×100).
(a): normal control group; (b): model control group; (c): low dose group; (d): middle dose group; (e): large dose group.
Fig.2  Pathological section of each group at week 12 by Van Giesons collagen staining (×100).
(a): normal control group; (b): model control group; (c): low dose group; (d): middle dose group; (e): large dose group.
groups6th week12th week
normal control47.25±12.5646.22±12.77
model control93.29±11.12**103.21±11.80**
low dose89.91±12.33**99.71±12.53**
middle dose63.44±11.94*□60.32±12.48*□
high dose60.98±12.94*□59.35±12.43*□
Tab.1  Effect of resveratrol on rat ALT
U/L
groups6th weekth week
normal control28.12±10.1225.23±9.87
model control32.23±10.17*34.22±10.23*
low dose31.91±9.62*33.12±11.02*
middle dose29.15±10.33□30.12±9.72*□
high dose29.17±11.05□29.35±11.16□
Tab.2  Effect of resveratrol on rat GLB
g/L
groups6th week12th week
normal control35.18±9.3335.23±9.43
model control28.9±10.71*25.22±10.82*
low dose29.92±9.35*27.12±10.55*
middle dose29.7±10.38*29.12±10.73*□
high dose30.81±10.18*29.35±11.36*□
Tab.3  Effect of resveratrol on rat ALB
g/L
groups6th week12fth week
normal control275.76±48.18276.23±43.77
model control669.17±58.32*700.22±60.21*
low dose493.4±53.11*□499.12±57.65*□
middle dose471.01±50.39*□432.12±56.12*□
high dose379.87±59.19○□380.35±52.13○□
Tab.4  Effect of resveratrol on rat HA
ng/mL
groupssixth weektwelfth week
normal control112.45±23.39110.23±25.58
model control222.65±36.76*267.22±30.79*
low dose169.41±29.98*□232.12±31.37*□
middle dose162.17±35.36*□199.12±36.11*□
high dose137.58±28.19○□170.35±32.32*□
Tab.5  Effect of resveratrol on rat pc III
μg/mL
groupsfourth week6th week8th week10th week12th week
normal control0.519±0.220.512±0.180.516±0.190.513±0.210.515±0.23
model control0.587±0.19*0.610±0.22*0.767±0.28*0.872±0.39*0.878±0.32*
low dose0.552±0.20○0.612±0.23*0.732±0.27*0.833±0.33*0.855±0.32*
middle dose0.555±0.17○0.616±0.22*0.723±0.34*0.750±0.31*□0.755±0.33*□
high dose0.542±0.19○0.610±0.20*0.728±0.28*0.732±0.32*□0.763±0.21*□
Tab.6  Effect of resveratrol on rat integrin-β1 (riODE-Integrin-β1/GAPDH)
groups6th week12th week
normal control0.477±0.110.457±0.17
model control0.595±0.12*0.899±0.28*
low dose0.533±0.21*0.827±0.27*
middle dose0.497±0.11□0.720±0.23*□
high dose0.499±0.12□0.710±0.24*□
Tab.7  Effect of resveratrol on rat TGF-β (riODE- TGF-β/GAPDH)
groups6th week12th week
normal control0.512±0.180.515±0.19
model control0.601±0.12*0.878±0.21*
low dose0.612±0.17*0.855±0.20*
middle dose0.616±0.18*0.755±0.18*□
high dose0.611±0.19*0.763±0.24*□
Tab.8  Effect of resveratrol on rat TIMP-1 (riODE- TIMP-1/GAPDH)
Fig.3  Expressions of integrin-β1, TIMP-1 and TGF-β in different stages of hepatic fibrosis in the model control group. TIMP-1: tissue inhibitor of metalloproteinase-1; TGF-β: tumor growth factor-β.
1 Scoazec J Y. Expression of cell-matrix adhesion molecules in the liver and their modulation during fibrosis. J Hepatol , 1995, 22(2 Suppl): 20-27
2 Levine D, Rockey D C, Milner T A, Johannes M. Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis. Am J Pathol , 2000, 156 (6): 1927-1935
3 Zhou X, Zhang Y, Zhang J, Zhu H, Zhou X, Du W, Zhang X, Chen Q. Expression of fibronectin receptor, integrin alpha 5 beta 1 of hepatic stellate cells in rat liver fibrosis. Chin Med J (Engl) , 2000, 113(3): 272-276
4 Nejjari M, Couvelard A, Mosnier J F. Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C. J Pathol , 2001, 195(4): 473-481
doi: 10.1002/path.964
5 Arloni V, Romanelli R G, Pinzani M. Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells. Gastroenterology , 2003, 110(4): 1127-1136
doi: 10.1053/gast.1996.v110.pm8613002
6 Yamauchi M, Mizuhara Y, Maezawa Y. Serum levels of integrins in chronic liver diseases. Pathol Res Pract , 2004, 190(9-10): 984-992
8 Yang C, Zeisberg M, Mosterman B. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology , 2003, 124(1): 147-159
doi: 10.1053/gast.2003.50012
9 Xu X, Li Y M, Ji H, Hou C Z. Changes of ECM and CAM gene expression profile in the cirrhotic liver after HCV infection: analysis by cDNA expression array. World J Gastroenterol , 2005, 11(14): 2184-2187
10 Shakado S, Sakisaka S, Noguchi K. Effects of extracellular matrices on tube formation of cultured rat hepatic sinusoidal endothelial cells. Hepatology , 2005, 22(3): 969-973
11 Humphries M J. Integrin structure. Biochem Soc Trans , 2000, 28 (4): 311-339
doi: 10.1042/0300-5127:0280311
12 Chigaev A, Zwartz G, Graves S W. Alpha4beta1 integrin affinity changes govern cell adhesion. J Biol Chem , 2003, 278(40): 38174-38182
doi: 10.1074/jbc.M210472200
13 Marra F, Pastacaldi S, Romanelli R G. Integrin-mediated stimulation of monocyte chemotactic protein-1 expression. FEBS Lett , 2001, 414(2): 221-225
doi: 10.1016/S0014-5793(97)01004-1
14 Fujii K. Ligand activation of overexpressed epidermal growth factor receptor results in loss of epithelial phenotype and impaired RGD-sensitive integrin function in HSC-1 cells. J Invest Dermatol , 2003, 107(2): 195-202
doi: 10.1111/1523-1747.ep12329606
16 Kato R, Kamiya S, Ueki M. The fibronectin-derived antiadhesive peptides suppress the myofibroblastic conversion of rat hepatic stellate cells. Exp Cell Res , 2001, 265(1): 54-63
doi: 10.1006/excr.2001.5179
17 Carloni V, Romanelli R G, Pinzani M. Focal adhesion kinase and phospholipase C gamma involvement in adhesion and migration of human hepatic stellate cells. Gastroenterology , 2001, 112(2): 522-531
doi: 10.1053/gast.1997.v112.pm9024306
18 Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis , 2001, 21(3): 397-416
doi: 10.1055/s-2001-17554
19 Moore C, Shen X D, Fondevila C. Fibronectin-alpha4beta1 integrin interactions modulate p42/44 MAPK phosphorylation in steatotic liver cold ischemia-reperfusion injury. Transplant Proc , 2005, 37(1): 432-434
doi: 10.1016/j.transproceed.2004.12.206
20 Iwamoto H, Sakai H, Nawata H. Inhibition of integrin signaling with Arg-Gly-Asp motifs in rat hepatic stellate cells. J Hepatol , 2000, 29 (5): 752-759
doi: 10.1016/S0168-8278(98)80256-0
21 Milliano M T, Luxon BA. Initial signaling of the fibronectin receptor (alpha5beta1 integrin) in hepatic stellate cells is independent of tyrosine phosphorylation. J Hepatol , 2003, 39(1): 32-37
doi: 10.1016/S0168-8278(03)00161-2
22 Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver , 2000, 18(1): 2-13
23 Danen E H, Lafrenie R M, Miyamoto S. Integrin signaling: cytoskeletal complexes, MAP kinase activation, and regulation of gene expression. Cell Adhes Commun , 2003, 6(2-3): 217-224
24 Yoshimoto N, Togo S, Kubota T. Role of transforming growth factor-beta1 (TGF-beta1) in endotoxin-induced hepatic failure after extensive hepatectomy in rats. J Endotoxin Res , 2005, 11(1): 33-39
25 Wang H, Mengsteab S, Tag C G. Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol , 2005, 11(13): 929-936
26 Tian J W, Yang J X, Fu F H, Jiang W L, Wang Z H, Wang C Y. Protection effect of polydatin to primary cultured rat hepatic cell injury induced by ·OH. Zhongguo Yaolixue Tongbao , 2003, 19(11): 543-545 (in Chinese)
27 Zhong F, Luo S J, Tang S M. New progression of resveratrol inhibit cell proliferation. Zhongcaoyao , 2003, 34(5): 2-4 (in Chinese)
28 Jiang W Q, Sheng J F. Pharmaco-activity and mechanism of action of resveratrol. Progress in Pharmaceutical Sciences , 2003, 27(3): 159-162
29 Lu Q J, Qiong J, Liqing Weng .Effect of resveratrol on rat chronic hepatic fibrosis, Zhongguo Xinyao Zazhi , 2005, 14(7): 855-858 (in Chinese)
30 Hong Z Y, Gao Y, Zhan X H. Morphology research on giant knotweed rhizome in protection of liver ischemic damage of rat. Shijie Huaren Xiaohua Zazhi , 2000, 8(2): 162-164 (in Chinese)
[1] Jun Song, Yeping Huang, Wenjian Zheng, Jing Yan, Min Cheng, Ruxing Zhao, Li Chen, Cheng Hu, Weiping Jia. Resveratrol reduces intracellular reactive oxygen species levels by inducing autophagy through the AMPK-mTOR pathway[J]. Front. Med., 2018, 12(6): 697-706.
[2] Xuefu Wang, Zhigang Tian. γδ T cells in liver diseases[J]. Front. Med., 2018, 12(3): 262-268.
[3] Jianguo LIU, Zhe ZHANG, Jiechang GAO, Jiwen XIE, Lin YANG, Shenjun HU. Downregulation effects of beta-elemene on the levels of plasma endotoxin, serum TNF-alpha, and hepatic CD14 expression in rats with liver fibrosis[J]. Front Med, 2011, 5(1): 101-105.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed